Market Opportunity for Troponin Diagnostics Market Driven by Rise in Cardiovascular Diseases and Ageing Population

According to World Health Organization, more than 17 million people die from cardiovascular disease (CVD) across the globe annually.

The rising threat of CVD is a global matter of concern, especially in Asia-Pacific (APAC) as the region accounts for more than half of world’s cardiovascular burden, according to a study by Frost & Sullivan.

Consequently, the rising threat of CVD drives Troponin Diagnostics market in APAC due to the increasing incidence rates of Myocardial Infraction (MI) and aging population at rapid pace.

The overall market of cardiac biomarker (troponins) in APAC is estimated to grow at a Cumulative Annual Growth Rate (CAGR) of 12.3% reaching nearly US $320 million by 2021. The growth will be strongly contributed by cardiac troponins point-of-care test (POCT) segment and cardiac troponins lab-based tests segment.

The POCT and lab-based tests are expected to increase at a CAGR of 15.5% and 10.4% respectively in the same time frame.

The primary reason behind the fast growth of POCT compared to lab-based test is mainly due to its promising benefits to healthcare service providers and patients. The main advantages of POCT are:

  • Easy to use and portable
  • It is gaining interests from healthcare professionals as it provides quick turnaround time (TAT)
  • Significantly reduces the rising healthcare expenditure for the patients
  • The severe reimbursement cuts in lab-based tests further encourages the region’s healthcare sectors to adopt POCT than lab-based tests

Various measures taken to grow healthcare facilities by different nations also boost the adoption of innovative diagnostic tests in the region, particularly in POCT segment. Examples of adoption of diagnostic tests in various countries:

  • Indonesia – introduction of universal healthcare coverage in Indonesia and 100% FDI in private clinical labs across the country
  • Thailand – expansion of private healthcare facilities in Tier II cities across Thailand
  • Vietnam – expansion of private healthcare infrastructure in Vietnam

Regional markets with access to Asian countries such as China, Indonesia and India will emerge as key markets due to early commercial access as proposed by the new CE regulatory guidelines. This is likely to enhance the market share of almost all market participants such as Alere, Abbott, Roche and Siemens.

In order to tap the growing opportunities exposed by Cardiac Troponin Diagnostics market, these key players are focusing on increasing sensitivity, accuracy and TAT for their tests. Therefore, vendors will not only invest in identifying better biomarkers for diagnosis but also in the POCT market because the development of POCT devices is expected to offer competitive advantage to its market participants and unfolds opportunities worth millions of dollars.

For more information on Frost & Sullivan’s report, click here “Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021”.


Subarna Poudel is a researcher with Frost & Sullivan. He can be reached at subarna.poudel@frost.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s